Adult urologyDifferences in clinicopathologic features of prostate cancer between black and white patients treated in the 1990s and 2000s
Section snippets
Material and methods
The data from 362 consecutive patients undergoing RP at the Veterans Affairs New York Harbor Healthcare System were compiled and analyzed after the institutional review board approved the study. Patients who received neoadjuvant hormonal and/or radiotherapy were not included in the database. We compared the 227 patients in group 1, who had undergone surgery in the 1990s, with the 135 patients in group 2, who were treated from 2000 to 2004.
The patients self-identified themselves as black (n =
Results
Table I shows a comparison of the differences in the clinicopathologic variables between groups 1 and 2. The data in Table I demonstrate the worse clinicopathologic features of CaP in black patients who underwent RP in the 1990s (group 1) compared with the white patients treated during the same period. The black patients in group 1 were significantly younger and had a greater pretreatment PSA level, Gleason score, and pathologic stage than did the white patients. In group 2, the black patients
Comment
In this study, we examined the changes in the disparity of the clinicopathologic features of CaP between black and white patients at our equal-access institution between the 1990s and 2000s. Our results have demonstrated several important points. First, we observed a narrowing of the difference in the pathologic stage over time between the black and white patients, likely due to the significant stage migration at presentation among the black patients. Second, the previously observed disparity
Conclusions
We have shown that between the 1990s and 2000s, the disparity in pathologic stage and age at RP has diminished between black and white patients treated at the Veterans Affairs Medical Center in New York. Significant differences, however, remained in the pretreatment PSA level and Gleason score, suggesting that early screening is especially important for black patients. Additional follow-up and research are necessary to determine whether these findings are associated with greater rates of
References (19)
- et al.
Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting
J Urol
(1996) - et al.
Disease-free survival differences between African Americans and whites after radical prostatectomy for local prostate cancera multivariate analysis
Urology
(2002) - et al.
Survival in blacks and whites after treatment for localized prostate cancer
J Urol
(1996) - et al.
Race as an outcome predictor after radical prostatectomyresults from the Shared Equal Access Regional Cancer Hospital (SEARCH) database
Urology
(2002) - et al.
Predictors of extracapsular extension and positive margins in African American and white men
Urol Oncol
(2003) - et al.
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancerresults of a multicenter clinical trial of 6,630 men
J Urol
(1994) - et al.
Continuing trends in pathological stage migration in radical prostatectomy specimens
Urol Oncol
(2004) - et al.
Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy
J Urol
(2002) - et al.
The effect of race/ethnicity on prostate cancer treatment outcome is conditionala review of the Wayne State University data
J Urol
(2004)
Cited by (0)
This study was supported by Department of Defense DOD (PC040021 to I. Osman); and in part by the use of facilities at the Manhattan Veterans Affairs Medical Center, New York, New York.